Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

uirapuru0 13 posts  |  Last Activity: Feb 10, 2016 1:01 PM Member since: Oct 3, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • uirapuru0 by uirapuru0 Feb 10, 2016 1:01 PM Flag

    Spilling over to SQNM?
    SQNM up 9.7%

  • uirapuru0 uirapuru0 Jan 28, 2016 11:11 AM Flag

    LOL!
    Rounding error. 7.2% it is.

  • uirapuru0 by uirapuru0 Jan 21, 2016 3:24 PM Flag

    TROV up 55% SQNM 4%.

  • 32K block trade, up $.10
    Camber?

  • Reply to

    Nice partners

    by btommasino Jan 11, 2016 11:33 AM
    uirapuru0 uirapuru0 Jan 11, 2016 4:58 PM Flag

    Hopefully there is a hook in here somewhere that Camber knows about.
    Wishful dreaming, probably.

  • uirapuru0 by uirapuru0 Dec 18, 2015 12:19 PM Flag

    Very strange reverse correlation between the overall market and SQNM.

    SQNM seems to do better when the market is down significantly.

  • Reply to

    Not Good

    by btommasino Dec 9, 2015 9:27 AM
    uirapuru0 uirapuru0 Dec 9, 2015 10:01 AM Flag

    Didn't someone once say,

    "Don't bash the messenger".

  • Reply to

    Not a bad day

    by btommasino Dec 8, 2015 4:00 PM
    uirapuru0 uirapuru0 Dec 8, 2015 5:37 PM Flag

    In nature, Unicorns get screwed too! :-)

  • Reply to

    Good Luck all Longs!

    by meg.patrick Dec 7, 2015 3:34 PM
    uirapuru0 uirapuru0 Dec 8, 2015 10:47 AM Flag

    May be happening now. up 7%

  • Reply to

    IT HAPPENED! PR FROM SQNM

    by uirapuru0 Dec 2, 2015 5:21 PM
    uirapuru0 uirapuru0 Dec 2, 2015 5:34 PM Flag

    you are not the only one!

  • Sequenom Comments On U.S. Court Of Appeals For The Federal Circuit Decision On '540 Patent

    PR Newswire

    SAN DIEGO, Dec. 2, 2015

    SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today issued a statement on the decision by the U.S. Court of Appeals for the Federal Circuit on the Company's U.S. Patent No. 6,258,540 ("'540 Patent").

    The U.S. Court of Appeals for the Federal Circuit today announced that it denied Sequenom's petition for en banc re-hearing of the Court's earlier decision upholding the ruling of the United States District Court for the Northern District of California that the claims of Sequenom's '540 patent are not patent eligible under the patent eligibility criteria established by the Supreme Court's Mayo Collaborative Services v. Prometheus Laboratories decision. This result was not unexpected given the earlier ruling by a three-judge panel of the Court of Appeals that said it was "bound by the sweeping language of the test set out in Mayo." However, denial of the petition was considered as a necessary first step to having the case potentially heard on appeal by the Supreme Court of the United States.

    In concurring opinions, three Circuit Judges expressed concern that the current interpretation of the Mayo decision may discourage development and disclosure of new diagnostic and therapeutic methods in the life sciences, which are often driven by discovery of new natural laws and phenomena. However, the Judges stated that despite the claims reciting "innovative and practical uses" for circulating, cell-free fetal DNA, they are bound by the language of Mayo, and any further guidance must come from the Supreme Court, not the U.S. Court of Appeals for the Federal Circuit. In a dissenting opinion, Circuit Judge Newman expressed her view that "the new diagnostic method here is novel and unforeseen, and is of profound public benefit" and stated: "I agree with my colleagues that this case is wrongly decided. However, I do not share their view that this incorrect decision is required by Supreme Court precedent."

    As previously stated, as a practical matter, Sequenom believes that the ruling has little business impact as it has been operating under the District Court's invalidity ruling since October, 2013 and due to the pooling arrangement of NIPT intellectual property entered into with Illumina, Inc. in December, 2014. In addition, valid and enforceable patents with claims equivalent to those of the '540 Patent are issued in Europe, Japan, Hong Kong, Canada and Australia.

    Sequenom understands that patent eligibility under 35 U.S.C. section 101 is an emerging and complex set of issues and is considering a further appeal to the Supreme Court of the United States.

  • Reply to

    NEWS

    by btommasino Dec 2, 2015 10:27 AM
    uirapuru0 uirapuru0 Dec 2, 2015 10:49 AM Flag

    That was our last chance for a Hail Mary pass in the final minutes of the game.
    Now we are just going to have to slog through the eternally gloomy tunnel with management, and no noticeable light at the end of the tunnel. Pffft!

  • Reply to

    NEWS

    by btommasino Dec 2, 2015 10:27 AM
    uirapuru0 uirapuru0 Dec 2, 2015 10:35 AM Flag

    No surprise, but what a shame.
    Now that that is out of the way, what next?

AFFY
0.0751-0.0064(-7.85%)Feb 12 3:27 PMEST